Alpha-mannosidosis is a rare genetic disorder characterized by a deficiency of the enzyme alpha-D-mannosidase. Alpha-mannosidosis is best thought of as a continuum of disease that is generally broken down into three forms: a mild, slowly progressive form (type 1); a moderate form (type 2); and a severe, often rapidly progressive and potentially life-threatening form (type 3).
The symptoms and severity of the disorder are highly variable. Signs may include distinctive facial features, skeletal abnormalities, hearing loss, intellectual disability, and dysfunction of the immune system. Alpha-mannosidosis is caused by mutations of the MAN2B1 gene. This genetic mutation is inherited as an autosomal recessive trait.
Podcast Episodes
Videos
Alpha-Mannosidosis Overview
Laura Buch, physician assistant who practices medical genetics at the Greenwood Genetic Center in South Carolina provides an overview of alpha-mannosidosis.
(Video length: 2 minutes)
Signs and Symptoms of Alpha-Mannosidosis
Dr. Reid Sutton, Clinical Geneticist and Clinical Biochemical Geneticist at Baylor College of Medicine and Texas Children’s Hospital in Houston, discusses some of the signs and symptoms of alpha-mannosidosis.
(Video length: 5 minutes)
Diagnosing Alpha-Mannosidosis
Dr. Markey McNutt, Clinical Geneticist at the University of Texas Southwestern Medical Center in Dallas. discusses challenges of diagnosing alpha-mannosidosis.
(Video length: 4 minutes)
Mom’s Perspective of Alpha-Mannosidosis
Rhonda Skipper, a mom of two boys (Dale and Matt) who are living with alpha-mannosidosis.
(Video length: 4 minutes)
Additional Resources
Information Disclaimer
The CheckRare learning platform is designed to help users better understand rare diseases, research, and medical effectiveness. Individuals are urged to consult with qualified health care providers for specific diagnosis and treatment challenges and for answers to personal health care questions. Information on CheckRare is only intended as general summary information and to raise awareness about rare diseases and orphan drugs, current and emerging treatment options, clinical trial updates, and genetic and diagnostic testing. Users are advised to consult appropriate health care professionals for more information on any of these issues.